Department of Ophthalmology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain.
Ophthalmologica. 2011;226(3):103-9. doi: 10.1159/000328980. Epub 2011 Jun 30.
To evaluate the efficacy and safety of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) due to pathological myopia (PM).
This retrospective case series studied outcomes in patients with CNV secondary to PM who were treated with intravitreal ranibizumab. Patients underwent complete ophthalmic evaluation, which included best-corrected visual acuity testing measured with Early Treatment Diabetic Retinopathy Study charts, optical coherence tomography (OCT) and baseline fluorescein angiography (FA). Indications for retreatment included the persistence of subretinal fluid on OCT as well as hemorrhages and new CNV on FA. Patients were followed for a minimum of 12 months.
We treated 29 eyes in 29 patients; the mean age was 56.8 years. Thirteen eyes were naïve, while 16 had been previously treated with photodynamic therapy or intravitreal bevacizumab. The mean initial visual acuity was 44.8 letters; at the 12-month follow-up, it was 53.7 letters. The mean OCT foveal thickness decreased by 35.3 μm. Patients received an average of 1.38 injections. Statistically significant differences were observed both in visual acuity and in central foveal thickness. All subgroups had favorable outcomes. None of the patients developed injection-induced complications or drug-related side effects.
Intravitreal injection of ranibizumab appears to be safe and efficacious in patients with CNV secondary to PM followed over a 12-month period.
评估玻璃体内雷珠单抗治疗病理性近视（PM）相关脉络膜新生血管（CNV）的疗效和安全性。
本回顾性病例系列研究纳入了接受玻璃体内雷珠单抗治疗的 PM 继发 CNV 患者，对其结局进行了评估。所有患者均接受了全面的眼科评估，包括最佳矫正视力（采用早期糖尿病视网膜病变研究图表进行测量）、光学相干断层扫描（OCT）和基线荧光素血管造影（FA）检查。再治疗的指征包括 OCT 上仍存在视网膜下积液以及 FA 上出现出血和新的 CNV。所有患者均至少随访 12 个月。
我们共治疗了 29 只眼的 29 例患者，平均年龄为 56.8 岁。13 只眼为初治，16 只眼之前接受过光动力疗法或玻璃体内贝伐单抗治疗。初始平均视力为 44.8 个字母，12 个月随访时为 53.7 个字母。平均 OCT 中心凹厚度减少了 35.3μm。患者平均接受了 1.38 次注射。视力和中心凹厚度均有显著统计学差异。所有亚组均有良好的结局。无患者发生与注射相关的并发症或药物相关的不良反应。
玻璃体内注射雷珠单抗治疗 PM 继发 CNV 安全有效，患者在 12 个月的随访期间获益。
